October 14, 2024 09:51 AM EDT

Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Kyle LaHucik

Senior Reporter

Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company confirmed to Endpoints News.

The Swiss pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Catalent sells New Jersey plant to Belgian CDMO, plans moving HQ elsewhere

Exclusive: British startup raises $16M to find genes that rewind the epigenetic clock

FDA to reconsider removal of Lilly's GLP-1 drug from shortage list, a win for compounding pharmacies

Jasper shares rally as chronic hives drug scores in small, early trial

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

No­var­tis ends mid-stage IPF tri­al, will keep test­ing drug in PAH

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis ends mid-stage IPF trial, will keep testing drug in PAH